Human biopharmaceutical expands into veterinary medicine with new subsidiary

Photo: New Africa/Adobe Stock

Privo Technologies, a phase 3 clinical-stage biopharmaceutical company specializing in drug delivery and cancer treatment in the human healthcare space, recently announced the launch of a new subsidiary called Benevet Oncology. This new branch, according to the company, will use Privo’s drug delivery technologies to tackle unmet needs in veterinary medicine.

More specifically, BeneVet plans to adapt Privo’s platforms, which were originally created for human medicine, to treat animals. According to BeneVet, their therapies leverage nanotechnology, polymer science, and potent oncology drugs.² Moreover, their nanoengineered technology targets tumor and lymph nodes, offers immunomodulation and immunogenesis, has no systemic toxicity, employs chemo-housing nanoparticles, and more.²

“With a team of experienced veterinary oncologists, pharmaceutical researchers, and animal lovers, we focus on developing targeted therapies that attack cancer cells with fewer side effects, ensuring pets experience the highest quality of life possible,” BeneVet states on its website.²

BeneVet’s early research and development will be on cutaneous and subcutaneous solid tumors. This research consists of intratumoral therapies of solid tumors, with BeneVet using Privo’s PRV131 intratumoral injectable to deliver targeted treatment to tumors in cats and dogs with improved precision and fewer adverse effects.¹ According to BeneVet, the company’s investigational PRV131 injection has had no reports of toxicity or weight loss in cats, including following multiple intratumoral injections—a contrast to other chemotherapies, which some feline patients do not tolerate well.²

Additionally, the new subsidiary will work on topical treatment of shallow tumors through the development of sustained-release treatments that aim to offer long-term relief for chronic pain conditions in pets.

"Our pets are family members, and they deserve the same level of innovation and care that we dedicate to human health," Manijeh Goldberg, PhD, MS, MBA, CEO and founder of Privo Technologies, said in a company release.¹ "BeneVet will build on Privo's technological foundation to bring groundbreaking treatments to veterinary medicine, starting with solutions for conditions that currently have limited or inadequate options."

To make sure its solutions are clinically effective and practical for real-world use, BeneVet also plans to work with veterinarians, veterinary researchers, and pet owners. The company will also explore opportunities for collaboration with animal health organizations to drive progress in advancements in veterinary medicine through joint research.

"By creating BeneVet, we are reaffirming our commitment to innovation and extending it to improve the lives of our beloved companions," said Goldberg.¹ "This new chapter is a natural evolution of our mission to make impactful, science-driven advancements accessible to those who need them most."

References

1. Privo Technologies Inc. announces the launch of BeneVet Oncology: Advancing companion animal health through innovation. News release. Privo Technologies Inc. March 24, 2025. Accessed March 27, 2025. https://prnmedia.prnewswire.com/news-releases/privo-technologies-inc-announces-the-launch-of-benevet-oncology-advancing-companion-animal-health-through-innovation-302408525.html
2. About us. BeneVet Oncology. Accessed March 27, 2025. https://www.bene-vet.com/about.html